DefinitionThis section has been translated automatically.
Substance from the group of cytostatic drugs (anthracyclines).
Half-lifeThis section has been translated automatically.
30–33 h
You might also be interested in
IndicationThis section has been translated automatically.
Lymphomas, leukemias, solid tumors; Kaposi's sarcoma.
Dosage and method of useThis section has been translated automatically.
40-75 mg/m2 KO i.v. every 3-4 weeks Maximum cumulative dose 550 mg/m2 KO.
Notice! Under therapy and up to 3 months afterwards, women and men must practice effective contraception!
Undesirable effectsThis section has been translated automatically.
Dermatologic complications:
- Alopecia
- Pruritus
- Reactions at the infusion site
- Exanthema
- Flush
- Onycholysis
- Nail pigmentation
- Phlebitis
- Stomatitis(mucositis)
Rarely urticaria (depending on source: 0.01-3% of pat.)
Other:
- Gastrointestinal disorders
- Liver damage
- Hyperuricemia
- Spermatogenesis and ovulation disorders
- Hematopoiesis disorders
- Cardiotoxicity (cardiomyopathy).
InteractionsThis section has been translated automatically.
See Table 1.
ContraindicationThis section has been translated automatically.
Pregnancy, nursing.
PreparationsThis section has been translated automatically.
Adriblastine, DOXO-cell, Doxorubicin, Ribodoxo-L
LiteratureThis section has been translated automatically.
- Lybaek D et al (2006) Pegylated liposomal doxorubicin in the treatment of mycosis fungoides. Acta Derm Venereol 86: 545-547
TablesThis section has been translated automatically.
Main interactions of Doxorubicin
Acetylcysteine |
Cardiotoxicity ↓ |
Anthracyclines |
Cardiotoxicity ↑ |
Antihistamines |
Cardiotoxicity ↓ |
Cyclophosphamide |
Cardiotoxicity ↑ |
Cytarabine |
Intestinal necrosis |
Digoxin |
Cardiotoxicity ↓ |
Phenobarbital |
Doxorubicin effect ↓ |
Verapamil |
Cardiotoxicity ↓ |
Prof. Dr. med. Peter Altmeyer
